Pharmaceuticals, Biotechnology & Life Sciences

IQVIA’s Q4 2026 earnings jump 31.6% to $2.78 EPS as data‑analytics expansion fuels 10.6% revenue growth, positioning the company for robust RWE‑driven growth and higher margins.

Zoetis thrives as pet owners shift toward high‑value veterinary care, driving strong earnings through innovative antimicrobials, vaccines, and precision diagnostics.

Incyte’s FDA approval of Jakafi XR—once‑daily ruxolitinib for MPNs and GvHD—offers same efficacy with better adherence, while Australia’s axatilimab expands chronic GvHD options.

Gilead’s Q4 2025 earnings reveal steady antiviral revenue and rapid growth in oncology assets like Gidea, impacting investors and patient access in biopharma.

Pfizer’s recent corporate moves—expiring ASX convertible options and FDA‑approved VEPPANU—boost its financial health and expand precision breast‑cancer treatment options.

Read Natera’s latest SEC filing: a senior officer sold shares on May 1, 2026, highlighting the company’s equity‑compensation strategy and its impact on shareholder confidence and corporate governance.

Incyte’s FDA approval of Jakafi XR—an extended‑release, once‑daily ruxolitinib—could boost MPN and GVHD sales, improve adherence, lower costs, and drive higher‑value reimbursement contracts.

Alnylam Pharmaceuticals: contrasting analyst views, robust pipeline, regulatory shifts, and market risks explained – find out why investors should watch Q3 earnings.

Explore Zoetis’s 2026 Form 4 filing: how short‑term share trades and a five‑year RSU plan align exec incentives with shareholder value.

Amgen’s latest earnings reveal modest revenue growth, improving margins, and cautious optimism amid macro‑economic headwinds—how it navigates reimbursement, supply chain, and next‑gen biopharma technologies.